Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations
Video navigation menu
- Atherosclerotic CVD is caused by long-term exposure to elevated LDL-c levels 0:27
- Data supporting pharmacotherapeutic LDL-c lowering 2:19
- Novel agents allow safe LDL-c lowering to very low levels 3:48
- Moving from evidence to practical treatment recommendations 6:06
- The new ESC/EAS Dyslipidaemia Guidelines put extra focus on high-risk patients 7:34
What is the rationale underlying the new LDL-c target recommendation?
- A. Long-term, substantial lowering of LDL-c is needed to achieve clinically relevant CV risk reduction
- B. LDL-c is a driving and necessary factor in atherosclerotic plaque development
- C. The target level is just above the lower limit of the relationship between CV risk and achieved LDL-c
- D. The target level leaves enough LDL-c to maintain cell membrane integrity
This educational video is part of a series aimed to shed light on what is now established on LDL-c and the risks it confers, and how we can best manage elevated LDL-c levels and why.
Professor Ulrich Laufs, MD, PhD is Professor of Cardiology at the University of Leipzig in Germany.
This educational series is funded by an unrestricted educational grant provided by Amgen. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: